-
PRADO trial - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Study
EGAS50000000268
-
A neoadjuvant, phase II trial demonstrates efficacy and tolerability of Talimogene laherparepvec in cutaneous basal cell carcinoma (NeoBCC trial)
Study
EGAS50000000252
-
Clonal heterogeneity leads to secondary resistance in a melanoma patient after adoptive cell therapy with tumor-infiltrating lymphocytes
Study
EGAS50000000279
-
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Study
EGAS00001007709
-
Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma
Study
EGAS50000000287
-
WHOLE GENOME SEQUENCING OF CLEAR CELL RENAL CELL CARCINOMA IN VHL PATIENT
Study
EGAS50000000295
-
ScRNA-seq of human kidney immune cells of patients with ANCA-associated glomerulonephritis, Lupus Nephritis against a "healthy" nephrectomy control
Study
EGAS50000000159
-
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Study
EGAS00001004430
-
Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Study
EGAS50000000302
-
WES in HCCOs with varying Doxorubicin resistance
Study
EGAS50000000043